MedTrace Logo

Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide

NCT02710071 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2020-10-19

Study results available
· View outcomes & findings →

Summary

Patients who have obstructive sleep apnea (OSA) frequently stop breathing while they sleep. They often develop high blood pressure. We are not sure what drug is best to treat the high blood pressure. This study will give the patients nebivolol or hydrochlorothiazide (HCTZ) for 6 weeks after 2 weeks of placebo. The blood pressure response will be evaluated by 24 hour monitoring.

Conditions

Interventions

DRUG

Nebivolol

Nebivolol 5mg then nebivolol 10 mg

DRUG

Hydrochlorothiazide

Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg

Sponsors & Collaborators

Principal Investigators

  • Michael G. Ziegler, M.D. · Professor of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-04-30
Completion
2016-04-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02710071 on ClinicalTrials.gov